ClinicalTrials.Veeva
Menu

Find clinical trials for Multiple Myeloma in New Haven, CT

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Plasma Cell Cancer
Hematologic Cancer
Lymphoma
Cancer
Leukemia
Smoldering Multiple Myeloma
Non-Hodgkin Lymphoma

Multiple Myeloma trials near New Haven, CT, USA:

A Study of GC012F (AZD0120), a CAR T Therapy Targeting CD19 and BCMA in Subjects With Relapsed/Refractory Multiple Myeloma

a phase 1b/2, open-label, multicenter study of GC012F (AZD0120), a CD19/BCMA dual CART-cell therapy, in adult subjects with relapsed/refractory Multiple...

Enrolling
Relapsed/ Refractory Multiple Myeloma
Biological: GC012F (AZD0120)

Phase 1, Phase 2

AstraZeneca
AstraZeneca

Stony Brook, New York, United States and 12 other locations

bortezomib (Velcade) and dexamethasone works in treating smoldering multiple myeloma and preventing progression to active or sympto ...

Active, not recruiting
Multiple Myeloma
High-risk Smoldering Multiple Myeloma
Drug: Lenalidomide
Drug: Daratumumab

Phase 2

Omar Nadeem, MD

Stamford, Connecticut, United States and 5 other locations

(LD-Dex) (Cohort B) in subjects with relapsed or refractory multiple myeloma who have received a first or second line treatment of ...

Active, not recruiting
Multiple Myeloma
Drug: Dexamethasone
Drug: Daratumumab

Phase 2

Celgene
Celgene

Stamford, Connecticut, United States and 48 other locations

monotherapy (control) in participants with newly diagnosed multiple myeloma after undergoing autologous stem cell transplant. In Pa...

Enrolling
Multiple Myeloma
Drug: Lenalidomide
Drug: Elranatamab

Phase 3

Pfizer
Pfizer

Valhalla, New York, United States and 239 other locations

escalation (Part A and C) and expansion (Parts B and D), first-in-human clinical study of CC-93269 in subjects with relapsed and refractory multiple...

Active, not recruiting
Multiple Myeloma
Drug: CC-93269

Phase 1

Celgene
Celgene

New Haven, Connecticut, United States and 34 other locations

(Arm A) versus daratumumab in combination with bortezomib/dexamethasone (Arm B) in the participants with relapsed recurrent multiple myeloma...

Active, not recruiting
Multiple Myeloma
Drug: Bortezomib
Drug: Daratumumab

Phase 3

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Fairfield, Connecticut, United States and 143 other locations

Locations recently updated

drug"). The study is focused on participants with newly diagnosed multiple myeloma (NDMM) who are eligible for high dose chemothera...

Enrolling
Multiple Myeloma
Drug: Linvoseltamab

Phase 1, Phase 2

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Stony Brook, New York, United States and 27 other locations

Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spon...

Enrolling
Multiple Myeloma
Drug: Carfilzomib
Drug: Bortezomib

Phase 3

AbbVie
AbbVie

Bay Shore, New York, United States and 82 other locations

Locations recently updated

The purpose of this study is to assess BMS-986453 in participants with relapsed and/or refractory multiple myeloma (RRMM)....

Enrolling
Relapsed and/or Refractory Multiple Myeloma
Drug: Fludarabine
Drug: BMS-986453

Phase 1

Juno Therapeutics

New Haven, Connecticut, United States and 18 other locations

with dexamethasone and daratumumab (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in participants with relapsed or refractory multiple...

Enrolling
Multiple Myeloma
Drug: Bortezomib
Drug: Daratumumab

Phase 3

Celgene
Celgene

New Haven, Connecticut, United States and 278 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems